Expert view – The Octet HTX system: enabling multi-purpose screening of therapeutic biologics during development

In addition to accuracy in identifying functionally specific molecules, the other major requirement for technologies in mAb development is achieving throughput to support screening needs early in discovery and during process development. Technologies that can accurately identify the right targets while affording the throughput necessary for the screening of a large number of candidates would shorten the time required to develop these therapeutics and ultimately help lower costs.

ForteBio’s Bio-Layer Interferometry (BLI), through its flagship instrument the Octet® HTX system, is especially versatile in the screening of biologics during discovery, cell line development and bioprocessing. The system provides antibody discovery scientists with a single solution for monitoring antibody-antigen interactions for the selection of lead molecules and for performing titre in a high-throughput manner.

Additional characterisation of antibodies is also possible with the system being particularly versatile in epitope binning assays. The Octet HTX system can also be used in bioprocessing to assess critical quality attributes including glycan screening, host cell protein analysis and residual protein A detection, among others. Relatively easy-to-develop methods combining detection in a sample plate format allows for rapid assay optimisation that speeds the selection of optimal and high-quality antibodies earlier in the drug discovery process.